Enveda Raises $311M Series E to Advance AI-Discovered Nature-Based Drugs Into Clinical Trials

Funding Milestone for AI-Powered Drug Discovery

Enveda, a biotech startup leveraging artificial intelligence to identify pharmaceutical candidates from plants and microbes, has secured $311 million in Series E funding at a $2 billion valuation. The round was led by Catalio Capital Management, with participation from Iconiq and other investors. This funding doubles the company's valuation from $1 billion just twelve months earlier, reflecting accelerating investor confidence in AI-assisted drug discovery models.

The Enveda Model and Market Opportunity

Founded in 2019 by Viswa Colluru, a former early-stage employee at Recursion Pharmaceuticals, Enveda operates on a thesis that potent therapeutic compounds exist in nature—embedded in plants, fungi, and microbial organisms—rather than requiring synthesis from scratch. The company uses artificial intelligence and computational methods to expedite the screening and discovery process, identifying drug candidates that would take far longer to find through conventional laboratory approaches. This approach represents a significant departure from traditional pharmaceutical R&D, which typically relies on synthetic chemistry and high-throughput screening.

Clinical Progress and Near-Term Pipeline

Enveda has moved beyond the discovery phase and is now testing multiple candidates in human clinical trials, marking a critical inflection point for the company. The pipeline includes a drug targeting severe skin conditions and another designed to address weight management challenges in patients transitioning off GLP-1 medications—a particularly timely indication given the commercial success of drugs like semaglutide and tirzepatide. No AI-discovered drug has yet received FDA approval, positioning Enveda among a cohort of companies racing to achieve this historic milestone and validate the technology's therapeutic value.

Broader Context in AI Drug Discovery

Enveda's funding success reflects a broader wave of capital flowing into AI-assisted pharmaceutical development. Multiple startups are advancing AI-identified candidates into human testing, though the field remains in its infancy relative to traditional drug development. The ability to move from discovery to clinical trials—and potentially to regulatory approval—would represent a watershed moment for AI in biotech, demonstrating that computational approaches can identify novel, safe, and effective medicines. The company's focus on bioprospecting from natural sources differentiates it from competitors pursuing purely synthetic drug design or target optimization.